Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ALDX

Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALDX
DateTimeSourceHeadlineSymbolCompany
11/09/202406:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
05/09/202421:00Business WireAldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
03/09/202423:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
15/08/202406:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
15/08/202406:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
13/08/202408:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
13/08/202407:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
08/08/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
08/08/202421:00Business WireAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
08/08/202406:01Business WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
02/08/202407:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALDXAldeyra Therapeutics Inc
02/08/202406:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
02/08/202406:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALDXAldeyra Therapeutics Inc
20/06/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
20/06/202421:00Business WireAldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor RoundtableNASDAQ:ALDXAldeyra Therapeutics Inc
13/06/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
13/06/202421:00Business WireAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
12/06/202421:00Business WireAldeyra Therapeutics to Host Investor Roundtable Q&ANASDAQ:ALDXAldeyra Therapeutics Inc
08/06/202406:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
07/06/202406:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
07/06/202406:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
07/06/202406:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
29/05/202421:00Business WireAldeyra Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
08/05/202421:00Business WireAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
25/04/202421:00Business WireAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayNASDAQ:ALDXAldeyra Therapeutics Inc
18/04/202421:00Business WireAldeyra Therapeutics to Host Research & Development Day on April 25, 2024NASDAQ:ALDXAldeyra Therapeutics Inc
28/03/202422:00Business WireAldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
08/03/202408:54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALDXAldeyra Therapeutics Inc
08/03/202408:48Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALDXAldeyra Therapeutics Inc
08/03/202408:40Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ALDXAldeyra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALDX